Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This cohort study compared all cause mortality within 6 months after contracting pneumonia in patients who had been taking a statin prior to developing pneumonia against those who had not. Data were sourced from The Health Improvement Network database and validated for pharmacoepidemiological research; propensity scoring was used for comparative analysis of patients in the two subgroups. A total of 129 288 patients who had received a statin were matched with 600 241 patients who had not. Following exclusions and restrictions, 942 statin users and 3615 non-users were included in the analysis. Of these, 204 statin users and 1264 non-users died within 6 months of the date of diagnosis of pneumonia. The fully adjusted rate ratio for mortality between statin users and non-users was 0.67 (95% CI 0.49 to 0.87). An estimation of the number needed to treat to prevent one death within 6 months of an episode of pneumonia was 15.
The results of this study show that the risk of dying within 6 months of pneumonia is lower among patients established on statin treatment when the pneumonia occurred. The authors support a case for randomised trials of statins in patients with pneumonia to determine whether a short period of statin treatment could reduce mortality.
▶ Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642. doi:10.1136/bmj.d1642.